

Strensiq (asfotase alfa) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:	:	
PATIENT INSURANCE ID NUN	∕IBER:			
F YOU ARE NOT THE PATIENT OR THE PRESCRI	SHT (IN/CM): WEIGH BER, YOU WILL NEED TO SUBMIT A PHI DISCLO	SURE AUTHORIZATION FORM WITH THIS REC	QUEST WHICH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL D	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
■ NEW THERAPY	NEW THERAPY		Y INITIATED:	
DURATION OF THERAPY (SPE	CIFIC DATES):			
<u> </u>				

Continued on next page.



Page 1 of 3



Strensiq (asfotase alfa) **Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

NACRADED'S FIDST NIABAE.

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
□ Juvenile-onset hypophosphatasia □ Perinatal/infantile-onset hypophosphata	sia		
□ Other Diagnosis	ICD-10 Code(s):		
PRIOR AUTHORIZATION. Clinical Information: Was the patient less than or equal to a *Must send a copy of the patient's did Did the patient have low baseline alkatory of the patient a copy of the patient a copy of the patient a copy of the patient have low baseline alkatory of the	18 years of age at disease onset?* \(\text{ Yes} \) 18 years of age at disease onset?* \(\text{ Yes} \) 19 years of age at disease onset?* \(\text{ Yes} \) 10 years of age at disease onset?* \(\text{ Yes} \) 10 years of age at disease onset?* \(\text{ Yes} \) 11 years of age at disease onset?* \(\text{ Yes} \) 12 years of age at disease onset?* \(\text{ Yes} \) 13 years of age at disease onset?* \(\text{ Yes} \) 14 years of age at disease onset?* \(\text{ Yes} \) 15 years of age at disease onset?* \(\text{ Yes} \) 16 years of age at disease onset?* \(\text{ Yes} \) 17 years of age at disease onset?* \(\text{ Yes} \) 18 years of age at disease onset?* \(\text{ Yes} \) 19 years of age at disease onset?* \(\text{ Yes} \) 19 years of age at disease onset?* \(\text{ Yes} \) 10 years of age at disease onset?* \(\text{ Yes} \) 10 years of age at disease onset?* \(\text{ Yes} \) 11 years of age at disease onset?* \(\text{ Yes} \) 12 years of age at disease onset?* \(\text{ Yes} \) 13 years of age at disease onset?* \(\text{ Yes} \) 14 years of age at disease onset?* \(\text{ Yes} \) 15 years of age at disease onset?* \(\text{ Yes} \) 16 years of age at disease onset?* \(\text{ Yes} \) 17 years of age at disease onset?* \(\text{ Yes} \) 18 years of age at disease onset?* \(\text{ Yes} \) 19 years of age at disease onset?* \(\text{ Yes} \) 19 years of age at disease onset?* \(\text{ Yes} \) 10 years of age at disease onset?* \(\text{ Yes} \) 11 years of age at disease onset?* \(\text{ Yes} \) 12 years of age at disease onset?* \(\text{ Yes} \) 13 years of age at disease onset?* \(\text{ Yes} \) 14 years of age at disease onset?* \(\text{ Yes} \) 15 years of age at disease onset?* \(\text{ Yes} \) 16 years of age at disease onset?* \(\text{ Yes} \) 17 years of age at disease onset?* \(\text{ Yes} \) 18 years of age at disease onset?* \(\text{ Yes} \) 19 years of age age at disease onset?* \(\text{ Yes} \) 19 years of age age at disease onset?* \(\t	o □ No esultation notes. justed) at time of diagnosis?* d ALP substrate levels [elevated chanolamine (PEA) and/or elevated	
status, growth or radiographic finding Are there any other comments, diagno physician feels is important to this rev	response to Strensiq therapy demonstra s? Yes No oses, symptoms, medications tried or fa riew?	iled, and/or any other information the	
Please note: Not all drugs/diagnosis ar information is received.	e covered on all plans. This request may	be denied unless all required	
ATTESTATION: I attest the information the Health Plan, insurer, Medical Group information necessary to verify the account of the information of the informa	n provided is true and accurate to the be p or its designees may perform a routine curacy of the information reported on thi	audit and request the medical s form.	
Prescriber Signature or Electronic I.D.	Verification:ompanying this transmission contain confidential	health information that is legally privileged. If	
you are not the intended recipient, you are her	eby notified that any disclosure, copying, distribut have received this information in error, please no	tion, or action taken in reliance on the contents	

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 08/22/2018 CAT0234

and arrange for the return or destruction of these documents.

Page 2 of 3





Strensiq (asfotase alfa) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program
Attn: CP – 4201
P.O. Box 64811
St. Paul, MN 55164-0811

Magellan Rx MANAGEMENT.